Zelenetz A D
Division of Hematologic Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY 10021, USA.
Ann Oncol. 2006 May;17 Suppl 4:iv12-4. doi: 10.1093/annonc/mdj992.
Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy.
尽管联合使用利妥昔单抗可提高缓解率，但在诱导化疗中加入利妥昔单抗尚未被证实能延长单纯化疗的无进展生存期和总生存期。在首次缓解期，与维持使用干扰素α相比，高剂量治疗加干细胞救援可改善至治疗失败时间和无进展生存期。然而，复发率并未达到平台期。放射免疫疗法具有显著的单药活性，与化疗联合使用时可为加入利妥昔单抗或自体干细胞移植提供一个平台。靶向治疗也显示出前景，可能在维持治疗和/或初始治疗中发挥作用。
